Customer support

xie@china-sinoway.com
EnglishEnglish
banner
Products
Home

API

Gliclazide 21187-98-4

Gliclazide 21187-98-4

99% up by HPLC
  • Product Details

Product Information


Product name

Gliclazide

CAS No.

21187-98-4

Molecular Formula

C15H21N3O3S

Molecular Weight

323.4105

Quality Standard

99% up by HPLC, Medical Grade

Appearance

White powder


COA of Gliclazide

Item

Specification

Test Result

Characteristics

White or almost white powder

White powder

Solubility

Practically insoluble in water:

freely soluble in methylene chloride;

Sparingly soluble in acetone(96%); slightly soluble in alcohol (96%)

Conforms

M.P

162-166°C

164.0-164.5° C

Identification

Conform to the spectrum of the CRS Gliclazide

Conforms

Heavy metals

≤10ppm

<10ppm

Impurity B

≤2ppm

0.3ppm

Related substances

Impurity F ≤0.10%

<0.10%

Other single impurity ≤0.10%

<0.10%

Total of other impurities ≤0.2%

<0.13%

Loss on drying

≤0.25%

0.10%

Sulphated ash

≤0.1%

0.01%

Residual solvents

Ethyl acetate ≤0.5%

Below LOQ

Toluene ≤0.089%

Below LOQ

Assay (on dried basis)

99.0%-101.0%

99.5%

Conclusion

The Results Conforms With Enterprise Standards


Usage


Function of Gliclazide

Gliclazide is a second-generation sulfonylurea hypoglycemic drug, which is a secretion promoter. Its hypoglycemic mechanism is to selectively act on the β cells of the pancreatic islets to promote the secretion of insulin and increase the secretion of insulin after eating, so that the liver Glycogen production and output are inhibited, which is helpful for the prevention and treatment of diabetic microvascular disease. Gliclazide has a long and stable action time, and is generally used in elderly patients. Gliclazide is generally absorbed quickly after oral administration, reaching a peak in 3-4 hours, and 80% is excreted from the kidneys. If the kidney function is not good, attention should be paid. Less common side effects are gastrointestinal reactions, such as nausea and vomiting, and the incidence of hypoglycemia is less than that of other sulfonylureas. Gliclazide can be used alone or simultaneously with other hypoglycemic drugs. Its hypoglycemic level is practical and reliable, and it can be combined with biguanides, insulin sensitizers, DPP-4 inhibitors and insulin, and different combinations can be made according to different conditions of patients.


*Products under the patent are only for R&D use

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

Spironolactone
Spironolactone 52-01-7
EP8, USP38,99.95% up by HPLC, total impurities < 0.05%
Mupirocin powder
Mupirocin 12650-69-0
99% up by HPLC / GMP
Imatinib mesylate
Imatinib Mesylate 220127-57-1
In-house Standard
Ceftiofur sodium
Ceftiofur sodium 104010-37-9
In-house Specification
Thymopentin
Thymopentin 69558-55-0
99% up Medical Grade
Azilsartan
Azilsartan 147403-03-0
99% up, JP/ GMP / PMDA / DMF
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact